Sichenzia Ross Ference Carmel LLP represents Virax Biolabs Group Limited in a $5 Million Registered Direct Offering

Press Release – New York, NY – August 23, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax”), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, in a $5 million registered direct offering to certain institutional investors.

Virax issued an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The SRFC team was led by partners Greg Sichenzia, Barrett DiPaolo and Matt Siracusa and associate Benasz Hansotia